Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nie, Shaoping
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure	Completed	3	226	Europe, Canada, US, RoW	Bentracimab (PB2452) Infusion	SFJ Pharmaceuticals, Inc.	Hemorrhage, Urgent Surgery, Invasive Procedure	09/24	09/24
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)	Active, not recruiting	N/A	539	RoW	BuMA Supreme, BuMA™	Sino Medical Sciences Technology Inc.	Coronary Artery Disease	03/18	12/25
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)	Active, not recruiting	N/A	1000	RoW	BuMA Supreme	Sino Medical Sciences Technology Inc.	Coronary Artery Disease	05/19	12/25
Vandenbriele, Christophe
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure	Completed	3	226	Europe, Canada, US, RoW	Bentracimab (PB2452) Infusion	SFJ Pharmaceuticals, Inc.	Hemorrhage, Urgent Surgery, Invasive Procedure	09/24	09/24
Zhu, Zhixin
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure	Completed	3	226	Europe, Canada, US, RoW	Bentracimab (PB2452) Infusion	SFJ Pharmaceuticals, Inc.	Hemorrhage, Urgent Surgery, Invasive Procedure	09/24	09/24